BRIEF-Bausch + Lomb To Discontinue BL1107 Eye Drop Development For Glaucoma

Bausch + Lomb Corporation

Bausch + Lomb Corporation

BLCO

0.00

July 9 (Reuters) - Bausch + Lomb Corp BLCO.TO:

  • ANNOUNCES PHASE 2 RESULTS FOR GLAUCOMA NEUROPROTECTIVE CANDIDATE

  • PHASE 2 STUDY FOR BL1107 DOES NOT MEET PRIMARY ENDPOINT

  • TO DISCONTINUE BL1107 EYE DROP DEVELOPMENT FOR GLAUCOMA

  • TO BEGIN CLINICAL TRIALS FOR SUSTAINED-RELEASE IMPLANT FOR GA IN 2028

  • BL1107 PHASE 2 STUDY DOES NOT ACHIEVE KEY SECONDARY VISUAL FUNCTION ENDPOINTS

  • BL1107 PHASE 2 STUDY SHOWS NO NEW SAFETY SIGNALS

Source text: ID:nBw8W4Nvta

Further company coverage: BLCO.TO


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.